← back to search

Mette Kalager

University of Oslo · NO
Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include Colorectal Cancer Screening and Detection, Global Cancer Incidence and Screening, Genetic factors in colorectal cancer, and Gastric Cancer Management and Outcomes.
h-index
41
citations
8,736
works
238
NIH funding
primary concept
Medicine
email

Recent publications

Twenty-Three-Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer : A Randomized Trial.
2026cited by 0position: contributordoi
Fecal Microbiota Transplantation Versus Vancomycin for Primary <i>Clostridioides difficile</i> Infection
Annals of Internal Medicine 2025cited by 14position: middledoi
Fecal Microbiota Transplantation Versus Vancomycin for Primary &lt;i&gt;Clostridioides difficile&lt;/i&gt; Infection : A Randomized Controlled Trial.
2025cited by 11position: contributordoi
Effectiveness of Colonoscopy Screening vs Sigmoidoscopy Screening in Colorectal Cancer
JAMA Network Open 2024cited by 29position: middledoi
Estimated Lifetime Gained With Cancer Screening Tests
JAMA Internal Medicine 2023cited by 146position: lastdoi
Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case-Control Study.
2023cited by 1position: contributordoi
TABLE 3 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
Supplementary Figure 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 4 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
Supplementary Figure 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 5 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 4 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
Supplementary Figure 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
Data from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 6 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
FIGURE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
Data from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 7 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 3 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
FIGURE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
FIGURE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 6 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 5 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
FIGURE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
Supplementary Figure 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi
TABLE 7 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 35 papers (2020–2026) · 31 papers (2020–2026)Henriette C. Jodal · Oslo University Hospital27 papers (2020–2023)Leticia G. Leon · Erasmus MC25 papers (2023–2023)Eddymurphy U. Akwiwu · Amsterdam University Medical Centers25 papers (2023–2023)E Dekker · Crohn's and Colitis Canada25 papers (2023–2023)Monique van Leerdam · Molecular Oncology (United States)25 papers (2023–2023)Soufyan Lakbir · Vrije Universiteit Amsterdam25 papers (2023–2023)Manon C W Spaander · Amsterdam University Medical Centers25 papers (2023–2023)Veerle M.H. Coupé · Amsterdam University Medical Centers25 papers (2023–2023)Gerrit A. Meijer · University of Baltimore25 papers (2023–2023)Meike de Wit · The Netherlands Cancer Institute25 papers (2023–2023)Remond J. A. Fijneman · Translational Research in Oncology25 papers (2023–2023)Beatriz Carvalho · Universidade Estadual Paulista (Unesp)25 papers (2023–2023)Pien M. Delis-van Diemen · Dutch Cancer Society25 papers (2023–2023)Margriet Lemmens · Dutch Cancer Society25 papers (2023–2023)Dagmar Klotz · Oslo University Hospital25 papers (2023–2023)Michael Bretthauer · University of Oslo17 papers (2012–2026)Hans‐Olov Adami · Oslo University Hospital14 papers (2012–2024)Magnus Løberg · Oslo University Hospital11 papers (2013–2024)